Compare AbbVie Inc (ABBV) vs HP Inc (HPQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs HP Inc — how do they compare? AbbVie Inc trades at $253.88 (market cap $449.91B), while HP Inc trades at $23.82 (market cap $21.00B). The key difference: AbbVie Inc is far larger — about 21.4× HP Inc's market cap, and HP Inc pays the higher dividend (5.23%). Which is the better fit depends on your goals.
| ABBV | HPQ | |
|---|---|---|
Market Cap | $449.91B | $21.00B |
Sector | Health | Technology |
52-Week High | $261.07 | $29.35 |
52-Week Low | $184.85 | $18.20 |
Enterprise Value | $513.38B | $28.16B |
Dividend Yield | 2.72% | 5.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
HPQ trades at $22.96, up 4.7% today, with strong earnings momentum as it has beaten EPS estimates for three consecutive quarters. The stock shows attractive valuation metrics with a P/E of 8.37 and P/S of 0.37, while technical indicators signal bearish momentum despite oversold RSI conditions. Recent developments include strategic AI partnerships with OpenAI and Ferrari, positioning the company for potential growth in the AI PC market.
The outlook remains cautiously optimistic with analyst consensus at $22.00, slightly below current price. Key opportunities include AI PC adoption and margin expansion, while risks involve competitive pressures and declining profit margins. Institutional sentiment leans neutral with 55% hold ratings, suggesting balanced risk-reward for value-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →
